Fundraising Fox
SymbioCellTech
Salt Lake City, US · Utah LLC
Find your way into SymbioCellTech
Sign up to see every warm intro you have to SymbioCellTech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SymbioCellTech team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SymbioCellTech develops a cell therapy called "Neo-Islets" intended to treat Type 1 Diabetes without daily insulin injections or immunosuppressive anti-rejection drugs. The company targets the estimated 16 million people living with Type 1 Diabetes.
Founders & leadership
AG
Anna GoochCo-founder · Chief Scientific OfficerAnna Gooch holds a doctorate in cellular, viral, and molecular biology and brings 15 years of experience in cell therapy research and commercialization, including prior roles in clinical operations and preclinical research. She has been Chief Scientific Officer at SymbioCellTech since 2013, overseeing development of Neo-Islets cell therapy for Type 1 Diabetes and managing IND-enabling preclinical studies and regulatory preparation work.
CW
Christof WestenfelderCEO, President and Founder of SymbioCellTech, LLCChristof Westenfelder holds degrees in Biochemistry and Medicine from Germany and trained in Internal Medicine and Nephrology in Chicago, where he directed the Dialysis Program at the University of Illinois before joining the University of Utah as Section Chief of Nephrology at the VA Medical Center; his research has focused on regenerative medicine and stem cell therapies, including work on bone marrow-derived Mesenchymal Stromal Cells for kidney disease and the development of Neo-Islets for Type 1 Diabetes treatment.
Board
AZ
Axel ZanderManager of LLC
GR
George ReissManager of LLC
RM
Robert Maddock, IIIManager of LLC
PH
Phil HolmesManager of LLC
AG
Allen GardnerManager of LLC
SM
Susan McKeeverManager of LLC
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 3 rounds · 2014–2017
▶$286.1KraisedAug 2017 · 3 investors · BiotechnologyRule 506(b)
▶$286.1KraisedAug 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Allen GardnerDirector
- Phil HolmesDirector
- Axel ZanderDirector, Promoter
- Susan McKeeverExecutive Officer, Director
- Robert Maddock, LLCDirector
- Christof WestenfelderExecutive Officer, Director, Promoter
- Anna GoochExecutive Officer, Director
- George ReissDirector
- Offering amount
- $2M
- Amount sold
- $286.1K
- First sale
- Aug 2017
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
▶$1.9MraisedJun 2016 · 4 investors · BiotechnologyRule 506(b)
▶$1.9MraisedJun 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Axel ZanderDirector, Promoter
- George ReissDirector
- Robert Maddock, IIIDirector
- Anna GoochExecutive Officer, Director
- Phil HolmesDirector
- Christof WestenfelderExecutive Officer, Director, Promoter
- Allen GardnerDirector
- Susan McKeeverExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $1.9M
- First sale
- Jun 2016
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
▶$2.6MraisedJun 2014 · 7 investors · BiotechnologyRule 506(b)
▶$2.6MraisedJun 2014 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christof WestenfelderExecutive Officer, Director, Promoter
- Axel ZanderDirector, Promoter
- Robert Maddock, IIIDirector
- George ReissDirector
- Anna GoochExecutive Officer, Director
- Susan McKeeverExecutive Officer
- Offering amount
- $7M
- Amount sold
- $2.6M
- First sale
- Mar 2014
- Incorporated
- Limited Liability Company, Utah
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does SymbioCellTech do?
- SymbioCellTech develops a cell therapy called "Neo-Islets" intended to treat Type 1 Diabetes without daily insulin injections or immunosuppressive anti-rejection drugs. The company targets the estimated 16 million people living with Type 1 Diabetes.
- Who founded SymbioCellTech?
- SymbioCellTech was founded by Anna Gooch, Christof Westenfelder.
- How much funding has SymbioCellTech raised?
- SymbioCellTech has disclosed $4.8M raised across 3 rounds.
- Where is SymbioCellTech headquartered?
- SymbioCellTech is headquartered in Salt Lake City, US.